Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4

BIODESIX INC

2025-FY EPS reported -$4.67 revenue$88,499,000

Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.
Lung Diagnostics revenue $25.2M in Q4 (+47% YoY), $79.2M FY (+22% YoY); test volumes 18,000 Q4, 62,600 FY.
Development Services revenue $3.6M Q4 (+13% YoY), $9.3M FY (+41% YoY).
Cash $19.0M as of Dec 31, 2025, up 14% from Q3, including $2.3M ATM proceeds; core cash flat.
Management affirms positive Adjusted EBITDA for Q4 2025 based on strong revenue flow-through.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.